ZNF865

Across TCGA pan-cancer cohorts, ZNF865 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ZNF865 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ZNF865 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated ZNF865 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LUAD, and GBM are the cancer types where ZNF865 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Quartile	All	0.828	0.485	<.001	22	view →
LUAD	OS	Median	II,III,IV	0.424	0.791	.006	16	view →
GBM	DFS	Median	All	0.220	0.434	.034	5	view →
CCRCC	OS	Tertile	III,IV	0.292	0.945	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ZNF865–HNSC (OS)

Open the HNSC breakdown →